MARC details
000 -LEADER |
fixed length control field |
02780nas a22002297a 4500 |
003 - CONTROL NUMBER IDENTIFIER |
control field |
OSt |
005 - DATE AND TIME OF LATEST TRANSACTION |
control field |
20220530171316.0 |
006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS |
fixed length control field |
m|||||r|||| 00| 0 |
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION |
fixed length control field |
ta |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
fixed length control field |
171219t2017 sp ||||| |||| 00| 0 spa | |
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
International Standard Serial Number |
1526-8209 |
040 ## - CATALOGING SOURCE |
Transcribing agency |
Salus Infirmorum |
245 00 - TITLE STATEMENT |
Title |
Pretreatment Serum Concentration of Vitamin D and Breast Cancer Characteristics: A Prospective Observational Mediterranean Study / |
Statement of responsibility, etc. |
Giuseppe Buono, Mario Giuliano, Carmine De Angelis, Rossella Lauria, Valeria Forestieri, Matilde Pensabene, Dario Bruzzese, Sabino De Placido, Grazia Arpino |
500 ## - GENERAL NOTE |
General note |
PDF en biblioteca |
504 ## - BIBLIOGRAPHY, ETC. NOTE |
Bibliography, etc. note |
Bibliografía: p.563 |
520 8# - SUMMARY, ETC. |
Summary, etc. |
The aim of this trial was to correlate pretreatment serum vitamin D levels with breast cancer and with patients’characteristics. Deficient vitamin D levels correlated with more aggressive disease (ie, high grade<br/>node-positive breast cancer), and with a high body mass index. Should our findings be confirmed in large prospective studies, vitamin D could be used as an anticancer agent.<br/>Background: Recent studies of the correlation between breast cancer (BC) and vitamin D yielded contrasting results.<br/>Although preclinical and clinical evidence has implicated vitamin D in BC prevention and outcome, little is known about the link between vitamin D and specific BC histologically defined subtypes. In the attempt to clarify this association we correlated vitamin D levels with BC characteristics. Patients and Methods: We enrolled 220 pre- and postmenopausal women with early BC in this prospective observational trial. Data on the patients’ clinical and specific BC pathological characteristics were collected and related to vitamin D levels, stratified in deficient (< 20 ng/mL), insufficient (20-30<br/>ng/mL), and sufficient (> 30 ng/mL). BC subtypes were defined according to the 14th St Gallen Breast Cancer<br/>Conference. Results: Deficient vitamin D levels were correlated with Grade 3 (P ¼ .015) and node-positive (P ¼ .043) BC, and with a higher body mass index (P ¼ .017). Insufficient vitamin D levels were associated with estrogen receptor expression in the primary tumor (P ¼ .033). Vitamin D levels were unrelated to the histological molecular subtypes of BC.<br/>Conclusion: Deficient vitamin D levels were correlated with more aggressive disease, namely, node-positive high grade BC, and with obesity. Should our findings be confirmed in larger prospective studies, nutritional programs designed to reduce body weight, and vitamin D supplementation might be considered a BC prevention strategy. |
653 14 - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
aggressive features |
653 14 - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
BC immunohistochemically defined subtypes |
653 14 - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
BMI |
773 ## - HOST ITEM ENTRY |
Related parts |
-- 2017, v. 17, n7, p. 559-563 |
Title |
Clinical Breast Cancer |
942 ## - ADDED ENTRY ELEMENTS (KOHA) |
Source of classification or shelving scheme |
Universal Decimal Classification |
Koha item type |
Artículo de revista |